Genmab A/S (NASDAQ:GMAB) Shares Gap Up - What's Next?

Genmab A/S (NASDAQ:GMAB - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $20.23, but opened at $20.93. Genmab A/S shares last traded at $20.84, with a volume of 112,594 shares changing hands.

Analysts Set New Price Targets

A number of analysts have weighed in on GMAB shares. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. BMO Capital Markets reissued an "outperform" rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, January 8th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $45.20.

Genmab A/S Stock Performance

The stock has a market cap of $13.76 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 0.59 and a beta of 0.97. The business's 50 day moving average is $21.19 and its 200-day moving average is $24.10.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analysts' expectations of $838.20 million. During the same period in the prior year, the firm earned $0.47 EPS. Sell-side analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock worth $636,000 after buying an additional 12,654 shares during the period. Renaissance Technologies LLC lifted its position in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. Verition Fund Management LLC acquired a new position in shares of Genmab A/S during the third quarter worth $709,000. HighTower Advisors LLC purchased a new position in Genmab A/S in the third quarter valued at $273,000. Finally, FMR LLC raised its stake in Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company's stock valued at $6,782,000 after buying an additional 33,076 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.